SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

1/24/24 11:21:06 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $NTLA alert in real time by email

SC 13G/A 1 Intellia_Therap.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING INTELLIA THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 45826J105 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO:45826J105 13G Page 2 of 5 Pages 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 4,485,854 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 4,735,861 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,735,861 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.29% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 45826J105 13G Page 3 of 5 Pages ITEM 1. (A) NAME OF ISSUER INTELLIA THERAPEUTICS INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER 1 CONGRESS STREET, SUITE 1 BOSTON, MA 02114-2016 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 45826J105 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO:45826J105 13G Page 4 of 5 Pages ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS NOT APPLICABLE ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO:45826J105 13G Page 5 of 5 Pages ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION.

Get the next $NTLA alert in real time by email

Recent Analyst Ratings for

$NTLA

Date	Price Target	Rating	Analyst
3/2/2026		Mkt Perform → Outperform	William Blair
11/12/2025		Outperform → Peer Perform	Wolfe Research
11/11/2025	$8.00	Outperform → In-line	Evercore ISI
11/7/2025	$5.00	Neutral → Underweight	Analyst
10/28/2025	$14.00	Outperform → Sector Perform	RBC Capital Mkts
10/28/2025		Outperform → Mkt Perform	Bernstein
10/27/2025		Outperform → Mkt Perform	William Blair
10/27/2025		Buy → Neutral	Guggenheim

More analyst ratings

SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

1/24/24 11:21:06 AM ET

$NTLA

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $NTLA alert in real time by email

Recent Analyst Ratings for

$NTLA

Date	Price Target	Rating	Analyst
3/2/2026		Mkt Perform → Outperform	William Blair
11/12/2025		Outperform → Peer Perform	Wolfe Research
11/11/2025	$8.00	Outperform → In-line	Evercore ISI
11/7/2025	$5.00	Neutral → Underweight	Analyst
10/28/2025	$14.00	Outperform → Sector Perform	RBC Capital Mkts
10/28/2025		Outperform → Mkt Perform	Bernstein
10/27/2025		Outperform → Mkt Perform	William Blair
10/27/2025		Buy → Neutral	Guggenheim

More analyst ratings

SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NTLA

SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NTLA

$NTLA
Press Releases

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

$NTLA
SEC Filings

SEC Form 424B5 filed by Intellia Therapeutics Inc.

Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form S-8 filed by Intellia Therapeutics Inc.

$NTLA
Insider Trading

EVP, General Counsel Basta James was granted 46,080 shares and sold $16,688 worth of shares (1,211 units at $13.78), increasing direct ownership by 40% to 156,794 units (SEC Form 4)

President and CEO Leonard John M was granted 156,400 shares, increasing direct ownership by 15% to 1,169,739 units (SEC Form 4)

VP, Chief Accounting Officer Dube Michael P was granted 17,250 shares, increasing direct ownership by 33% to 69,527 units (SEC Form 4)

$NTLA
Analyst Ratings

Intellia Therapeutics upgraded by William Blair

Intellia Therapeutics downgraded by Wolfe Research

Intellia Therapeutics downgraded by Evercore ISI with a new price target

$NTLA
Insider Purchases

Director Cohen Fred E bought $1,402,500 worth of shares (150,000 units at $9.35), increasing direct ownership by 261% to 207,453 units (SEC Form 4)

Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

$NTLA
Large Ownership Changes